| Clinical data | |
|---|---|
| Trade names | Prohalone |
| Other names | Aloprogesterone; 6α-Fluoro-17α-bromoprogesterone; 6α-Fluoro-17α-bromopregn-4-ene-3,20-dione |
| Routes of administration | By mouth |
| Drug class | Progestogen;Progestin |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C21H28BrFO2 |
| Molar mass | 411.355 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Haloprogesterone, sold under the brand nameProhalone, is aprogestin medication which was previously marketed byAyerst but is now no longer available.[1][2][3]
Haloprogesterone, also known as 6α-fluoro-17α-bromoprogesterone or as 6α-fluoro-17α-bromopregn-4-ene-3,20-dione, is asyntheticpregnanesteroid and ahalogenatedderivative ofprogesterone.[1] It is specifically a derivative of17α-bromoprogesterone and is similar structurally tomedrogestone (6-dehydro-6,17α-dimethylprogesterone),medroxyprogesterone acetate (6α-methyl-17α-acetoxyprogesterone), and various other progestins derived from progesterone.[1]
Chemical syntheses of haloprogesterone have been published.[4]
Haloprogesterone wassynthesized in 1960 and was introduced for medical use by 1961.[1][5][6]
Haloprogesterone is thegeneric name of the drug and itsINNTooltip International Nonproprietary Name andUSANTooltip United States Adopted Name.[1][3]
Haloprogesterone was marketed under the brand name Prohalone.[1]